ClinicalTrials.gg
Not yet recruitingNCT07862946INOPOSALOUpdated Nov 4, 2026

Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

A Phase 2 interventional study of Inotuzumab Ozogamicin (IO) in Acute Lymphobkastic Leukemia and Adult, sponsored by PETHEMA Foundation. Not yet recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by PETHEMA Foundation · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Study contact changedNewly registered+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if Inotuzumab Ozogamicin works to prevent relapses after transplantation in adult high-risk B-cell precursor acute lymphoblastic leukemia treated with the PETHEMA ALL-2025 protocol.

The main questions it aims to answer are:

  • Do patients receiving Inotuzumab ozogamicin post-transplantation suffer less relapses than those patients not receiving this therapy (control group) within the ALL-2025 protocol?
  • Do patients receiving Inotuzumab ozogamicin show more adverse events and severe adverse events related with this treatment than those patients no receiving this intervention (control group)? Researchers will compare the relapse rate between patients receiving Inotuzumab Ozogamicin post-transplantation and patients not receiving Inotuzumab Ozogamicin post-trasnplantation within the ALL-2025 protocol.

Participants will receive 3 cycles of Inotuzumab Ozogamicin therapy. Treatment will be initiated from day +70 post-transplantation and a minimum interval of 30 days between consecutive administrations.

Read the detailed description

This is a single arm study in which participants with high-risk B-cell precurdsor acute lymphoblastic leukemia (BCP ALL) enrollled in the immunochemotherapy schedule according to PETHEMA ALL-2025 protocol will receive Inotuzimab Ozogamicin as post-transplantation therapy to prevent relapse. The relapse rate of the participants will be compared to that of high-risk BCP ALL patients receiving transplantation within the PETHEMA ALL-2025 protocol. In addition, the presence of adverse events and severe adverse events will also be monitored in order to know if this treatment is as safe as or comparable to that of patients not receiving this drug. A safety analysis will be performed in the first 5 patients with special consideration of haematological and hepatic toxicity.

Three doses of 0,5mg/m2 of Inotuzumab Ozogamicin will be given to participants at day +70 post-transplantation and a minimum interval of 30 days between consecutive administrations. All patients will receive treatment until treatment is completed, unacceptable toxicity, disease progression, patient withdrawal, loss of follow-up, end of study, study completion, or death, whichever is first. This regimen is intended as post-allo-HSCT relapse prophylaxis/maintenance rather than treatment of active relapsed disease. Patients will be monitored upto 24 months after the last drug infusion (month 3, 6, 9, 12, 18, 24).

02

Conditions studied

  • Acute Lymphobkastic Leukemia
  • Adult

Browse trials for

Keywords

  • Inotuzomab ozogamicin
  • B-cell acute lymphoblatic leukemia
  • allogeneic stem cell trasnplantation
  • relapse
03

In context

Lead sponsor

PETHEMA Foundation is the lead sponsor of 107 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is, in the investigator's opinion, willing and able to adhere/comply with visit schedule and other protocol requirements.
  2. Patient must be able to understand the study procedures.
  3. Patients aged ≥18 years at the time of signing the form.
  4. Patient must have an (ECOG) performance status score of ≤ 2.
  5. Patient with CD22-positive high risk ALL according to any of the following criteria:

    i. Definition of high risk ALL according to the PETHEMA LAL 2019 protocol criteria including MRD stratification at the end of induction and during treatment and adverse cytogenetics at diagnosis (hypodiploid karyotype, KMT2A (MLL) alterations, homozygous TP53 deletions/mutations, and IKZF1 and CDKN2A/B deletions).

ii. Patients who are in first CR at the time of transplantation, irrespective of MRD status as assessed by immunophenotypic study.

iii. Allo- from an HLA-identical, mismatched or haploidentical sibling or unrelated donor, with myeloablative, reduced toxicity or non-myeloablative conditioning.

iv. Stable hematopoietic engraftment defined by neutrophils >1000/μL for at least 3 consecutive days and >50000/μL for 7 days with transfusion independence and donor chimerism >90% assessed in peripheral blood.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to inotuzumab ozogamicin or known to inotuzumab ozogamicin or to any of its .
  2. Ph-positive lymphoblastic leukemia
  3. Cord blood .
  4. \<30 ml/minute.
  5. , GOT and GPT > 2 times the upper limit of the institution's reference values.
  6. History of previous liver disease or hepatic veno-occlusive disease/sinusoid obstruction syndrome.
  7. Active or C
  8. Fungal infection or relevant uncontrolled infection.
  9. Active grade 3-4 acute or acute or chronic hepatic graft-versus- host disease grade ≥2
  10. Graft-versus-host disease prophylaxis with sirolimus at enrolment that cannot be discontinued prior to initiation of trial treatment.
  11. Absence of haematological recovery
  12. Uncontrolled concomitant disease (cardiac, renal, pulmonary, psychiatric).
  13. Uncontrolled non-hematological tumor
  14. Any serious medical condition or psychiatric illness that would interfere in understanding of the form.
  15. Any serious medical condition that places the subject at an unacceptable risk if he or she participates in this study.
  16. Women who are pregnant or breastfeeding, or who intend to become pregnant during participation in the study, or women of who are unwilling or unable to use a highly effective method during treatment and for at least 8 months after the last dose; and male participants with female partners of childbearing potential who are unwilling or unable to use a highly effective contraceptive method during treatment and for at least 5 months after the last dose.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Inotuzumab Ozogamicin

    Drug: Inotuzumab Ozogamicin (IO)

Interventions

  • DrugInotuzumab OzogamicinStudies of Inotuzumab OzogamicinInotuzumab Ozogamicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Three doses of 0,5mg/m2 of Inotuzumab Ozogamicin will be given to participants at day +70 post-transplantation and a minimum interval of 30 days between consecutive administrations. All patients will receive treatment until treatment is completed, unacceptable toxicity, disease progression, patient withdrawal, loss of follow-up, end of study, study completion, or death, whichever is first.

06

What researchers measure

Primary outcomes

  1. Efficacy of Inotuzumab Ozogamicin (InO) in the prevention of relapse in terms of the relapse rate

    Evaluation of the efficacy of InO in terms of relapse rate, defined as percentage of patients who experience a relapse after achieving complete remission.

    Time frame: 24 months

  2. Efficacy of InO in the prevention of relapse in terms of the cumulative incidence of relapse (CIR)

    Evaluation of the efficacy of InO in terms of CIR, defined as time interval between the date of complete remission and the date of relapse, considering any death not related to relapse as a competing event.

    Time frame: 24 months

  3. Efficacy of InO in the prevention of relapse in terms of the disease-free survival (DFS).

    Evaluation of the efficacy of InO in terms of DFS, defines as time interval between the date of complete remission and relapse, death from any cause or last follow-up.

    Time frame: 24 months

Secondary outcomes

  1. Safety profile of treatment with InO after allogeneic hematopoietic stem cell trasnplantation (allo-HSCT) in terms of side effects, adverse events (AEs) and serious AEs (SAEs) related to treatment

    The safety profile of the treatment will be assessed based on: * Incidence of AEs. * Percentage of patients discontinuing therapy due to AEs. * Percentage of patients requiring dose modifications due to AEs. * Incidence of SAEs. * Changes in laboratory analysis from the hematology and blood chemistry panel. * Incidence of deaths and primary cause of death. A safety analysis will be performed in the first five patients with special consideration of haematological and hepatic toxicity.

    Time frame: 24 months

  2. Centralized study the minimal residual disease (MRD) in bone marrow (BM)

    MRD will be centrally analized in BM prior to drug administration, as well as at 3-, 6-, 9-, 12-, 18- and 22-months post allo-HSCT by Next Generation Flow Cytometry. Negative MRD will be considered when there is \<0.01% of leukemic cells among all cell counts.

    Time frame: 22 months

  3. Analysis of the immune reconstitution in peripheral blood

    Analysis of the immune reconstitution in peripheral blood prior to drug administration and at 3-, 6-, 9-, 12-, 18- and 22-months post allo-HSCT, evaluated by immunophenotypic study (NGF) of specific markers of B-cells, T-cells and myeloid cells, among others.

    Time frame: 22 months

  4. Analyse the cumulative incidence of graft failure and acute and chronic graft-versus-host disease (GVHD).

    Analysis of the cumulative incidence of graft failure, defined as time interval from allo-HSCT to graft failure (failure to achieve sustained engraftment of donor cells). Cumulative incidence of acute GVHD (aGVHD), defined as time interval from allo-HSCT to aGVHD, staged and graded according to the MAGIC criteria previously published. Cumulative incidence of chronic GVHD (cGVHD) as time interval from allo-HSCT to cGVHD, based on the NIH criteria previously published.

    Time frame: 24 months

07

Study locations

10 sites
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2026
First posted
Oct 7, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Oct 30, 2030
CompletionEst.
Oct 30, 2030
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Spain)
  • Complejo Hosp. Regional Virgen del Rocío · Seville, Spain
  • Hospital Universitari i Politecnic La Fe · Valencia, Spain
Show 2 removed
  • Complejo Hosp. Regional Virgen del Rocío · Seville, Spain
  • Hospital Universitari i Politecnic La Fe · Valencia, Spain
Nov 4, 2026
Contact
Study contact changed: added m•••@scsalud.es. See the current contact
Nov 4, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Spain)
    • Complejo Hosp. Regional Virgen del Rocío · Seville, Spain
    • Hospital Universitari i Politecnic La Fe · Valencia, Spain
    Show 2 removed
    • Complejo Hosp. Regional Virgen del Rocío · Seville, Spain
    • Hospital Universitari i Politecnic La Fe · Valencia, Spain
    Contact Study contact changed: added m•••@scsalud.es. See the current contact
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07862946
Lead sponsor
PETHEMA Foundation
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Oct 30, 2030 (estimated)
Completion
Oct 30, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Alfonso Santiago
Contact
asm@fundacionpethema.es
+34 91 626 62 32
Arancha Bermúdez
Contact
maria.bermudez@scsalud.es
Arancha Bermúdez
study chair · Hospital Marqués de Valdecilla
Vitor Botafogo
study chair · ICO-Hospital Germans Trias i Pujol

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inotuzumab Ozogamicin

Start the discussion